ポナチニブ
↑ “Iclusig (ponatinib) Tablets, for Oral Use. Full Prescribing Information”. ARIAD Pharmaceuticals, Inc. 26 Landsdowne Street, Cambridge, MA 02139-4234. 2016年10月2日閲覧。
↑ “Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant”. J. Med. Chem. 53 (12): 4701–19. (June 2010). doi:10.1021/jm100395q. PMID 20513156.
↑ “AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance”. Cancer Cell 16 (5): 401–12. (November 2009). doi:10.1016/j.ccr.2009.09.028. PMC 2804470. PMID 19878872. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804470/.
↑ “FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales”. FDA Drug Safety Communication. U.S. Food and Drug Administration (2013年10月31日). 2013年11月3日閲覧。
↑ Grady D (2013年10月31日). “Serious Danger of Blood Clots Halts Sale of Leukemia Drug”. Business. New York Times.